Integrated Biosciences, a biotechnology company pioneering the use of synthetic biology and machine learning to develop next-generation therapeutics for age-related diseases, announced that it has closed a $17.2 million seed financing, led by Sutter Hill Ventures with participation from Root Ventures, Civilization Ventures, Illumina Ventures Labs, Lifespan Vision Ventures, Overlap Holdings, SH Fund (Sabrina Hahn), Conscience VC, Mission BioCapital, Reinforced Ventures, Polymath Capital, Michael Stoppelman, and Vijay Pandurangan. The company also announced that Keith Loebner, Ph.D. has been appointed to the company's Board of Directors and that Karl Sylvester, M.D., Uri Alon, Ph.D., and Wendy B. Young, Ph.D. have been appointed as advisors to the company.

Integrated Biosciences is a biotechnology company pioneering novel approaches that combine synthetic biology and AI-driven small-molecule drug discovery to produce next-generation therapeutics targeting age-related diseases.